SCHEMBL6201155

SCHEMBL6201155

CCOC(=O)c1cnc2c(F)cc(C)cc2c1O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.45
MAPT P10636 6/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
JMJD6 Q6NYC1 1/20 0.42
GLA P06280 1/20 0.41
RAD52 P43351 1/20 0.41
UHRF1 Q96T88 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6200613 0.90 KMT2A (0.45) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL20138081 0.87 MAPK1 (0.44) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL26632758 0.87 MAPT (0.47) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL6200159 0.87 MAPT (0.42) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL6199896 0.87 MAPT (0.42) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL31255110 0.87 MAPT (0.47) MAPTKMT2AMEN1GAAKDM4E
SCHEMBL11240555 0.86 THRB (0.57) THRBMAPTKMT2AMEN1GAA
SCHEMBL4652568 0.86 DPP4 (0.50) MAPTKMT2AMEN1KDM4EALDH1A1
SCHEMBL12794277 0.86 KMT2A (0.55) THRBMAPTKMT2AMEN1GAA
SCHEMBL538577 0.85 KMT2A (0.46) MAPTKMT2AMEN1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2011-03-17 US disclosed
EP-1042295-B1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN CO LLC (US) 2005-09-07 EP disclosed
EP-1042295-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-10-11 EP disclosed
US-6093732-A PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION PHARMACIA & UPJOHN COMPANY (US) 2000-07-25 US disclosed
WO-1999032450-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 THRB 243/4885MAPT 461/4885KMT2A 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.